ADMA Biologics (NASDAQ:ADMA – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $7.50 price objective on the biotechnology company’s stock, up from their prior price objective of $6.00. HC Wainwright’s price target would […]